🇺🇸 FDA
Patent

US 10392391

Compounds useful as inhibitors of ATR kinase

granted A61PA61P1/02A61P1/04

Quick answer

US patent 10392391 (Compounds useful as inhibitors of ATR kinase) held by Vertex Pharmaceuticals Incorporated expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P1/02, A61P1/04, A61P1/16, A61P1/18